Gland Pharma Ltd AGM

Gland Pharma Stock Gains 7% as Q3 Revenue Climbs 22.5% to ₹1,695.3 Crore

 Copy Link

The European business reported a 54 percent year on year surge in topline during the quarter.

Top Stocks for Today - 8th January 2026

 Copy Link

Here are some of the stocks that may see significant price movement today: Infosys, Tata Steel, Cipla Limited, etc.

Top Stocks for Today - 4th November 2025

 Copy Link

Here are some of the stocks that may see significant price movement: Bharti Airtel, Cipla, Gland Pharma, etc.

Top Stocks for Today - 14th July 2025

 Copy Link

Here are some of the stocks that may see significant price movement today: Avenue Supermarts, BEML, Gland Pharma, etc.

Gland Pharma Gets USFDA Clearance for Visakhapatnam Facility

 Copy Link

The receipt of the EIR marks the formal closure of the US health regulator’s pre-approval inspection, which was conducted between February 19 and February 25, 2025.

Top Stocks for Today - 5th June 2025

 Copy Link

Here are some of the stocks that may see significant price movement today: Hindustan Aeronautics, Gland Pharma, REC, etc.

Gland Pharma gets USFDA approval for blood pressure drug

 Copy Link

Gland Pharma also established that its version is bioequivalent and therapeutically equivalent to the reference listed drug.

Gland Pharma Q4 Net Profit Declines 3.1% to ₹186.5 Crore; Revenue Down 7.3% YoY

 Copy Link

Gland Pharma net profit was at ₹186.5 crore as against ₹192.4 crore in the year-ago quarter of FY24.

Gland Pharma Gets USFDA Nod for Glaucoma Drug

 Copy Link

Gland Pharma has secured exclusive rights as the first-to-file sponsor of this generic product. This makes it eligible for 180 days of marketing exclusivity in the US

USFDA Issues Three Observations to Gland Pharma's Visakhapatnam Facility

 Copy Link

The FDA conducted the pre-approval inspection (PAI) from Feb. 19, 2025, to Feb. 25, 2025, as part of the regulatory process for sterile APIs.